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other pathogens, could influence the susceptibility to the athero-
genic effect of infection with a particular pathogen like CP.
Consequently, this finding suggests that “susceptibility” factors
could make subjects more likely to develop CAD when infected
with a particular pathogenic agent.
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REPLY
We greatly appreciate the comments of Dr. Auer and colleagues
regarding our article recently published in the Journal of the
American College of Cardiology (1).
Chlamydia pneumoniae (CP) was often reported to be associated
with coronary artery disease (CAD) in seroepidemiologic studies,
but the potential contribution of CP to CAD remains controver-
sial. As shown in our article (1), Auer et al. also found no
significant difference in the CAD prevalence between patients with
and without CP seropositivity. However, CP organism was de-
tected within atheroma by direct immunofluorescence and poly-
merase chain reaction (PCR), and CP infection was shown to
accelerate atherosclerosis in a rabbit model. We agree with Dr.
Auer and colleagues that some triggers like cytokine gene poly-
morphisms or additional exposure to other pathogens could
influence susceptibility to the atherogenic effect of CP infection.
Regarding genetic factors for CAD associated with CP infec-
tion, we reported that two polymorphisms of interleukin (IL)-1
genes play a role in the development of CAD, especially myocar-
dial infarction, in patients with CP infection (1). However, other
cytokine gene polymorphisms, such as IL-6 and IL-10, were also
reported to be associated with CAD as well as inflammatory
diseases. In addition to the IL-1 gene polymorphisms, they may be
contributing to the development of CAD associated with CP
infection. We will continue to seek genetic factors influencing the
susceptibility to CAD associated with CP or other infections.
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Patients With CHF and Depression
Have Greater Risk of Mortality and
Morbidity Than Patients Without Depression
With great respect and interest, we read the recently published
study by Vaccarino et al. (1) in the Journal. That study supports our
previous findings, presented at the annual meetings of the Amer-
ican Psychiatric Association (2) and the American Heart Associ-
ation (3) and was just published a day before in the Archives of
Internal Medicine this month, that the short-term prognosis of
patients with heart failure (HF) and comorbid depression is much
worse than that of such patients without depression.
Vaccarino and colleagues assessed the level of depressive symp-
toms by means of the Geriatric Depression Scale (GDS) on 391
patients aged 50 or older who were hospitalized with HF. They
followed the patients for six months and assessed mortality and
functional capacity in activities of daily living (ADL). They found
that mortality at six months was two to three times higher in
patients with greater depressive symptoms than in those with lesser
depressive symptoms or those considered to have normal mood.
Patients with moderate to severe depressive symptoms also showed
significant functional declines during follow-up. Apparently, the
covariates of age, gender, race and education were not associated
with the relationships of depression to mortality and functional
decline; but when the statistical model was adjusted for other
variables, such as prior infarction, diabetes, prior admission for
HF, certain limiting factors of ADL and several baseline clinical
features (systolic blood pressure, serum creatinine, pulse and left
ventricular ejection fraction), in addition to these demographic
characteristics, the adverse relation between depression and mor-
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tality no longer existed. The adverse effects of moderate depression
on functional decline were also diminished (see their Table 3 [1]).
These results raise two concerns. First, as the investigators noted
in their study, GDS is a valid measure for depressive symptoms
among the elderly, but it is not equivalent to a clinical diagnosis of
depression through standard diagnostic interviewing. Second, how
many variables to include as adjustment factors (given the number
of events) and the identification of potentially confounding factors
remain as challenges.
We studied 374 hospitalized patients similar to those in the
Vaccarino et al. (1) study, except our cohort included subjects ages
18 and up, between March 1997 and June 1998 (4). We used the
Beck Depression Inventory (BDI) to screen for the presence of
depressive symptoms. Patients with a BDI score 10 underwent
standardized psychiatric diagnostic interviewing for the clinical
diagnosis of major depressive disorder according to DSM-IV criteria.
Patients were followed at 3 months and 12 months for repeat
hospitalization and mortality. We found that the mortality rate in HF
patients with major depression was about 2.5 times higher than in HF
patients without depression (BDI score 10) at 12 months, and a
similar trend was noted at 3 months. The incidence of repeat
hospitalization also followed a similar pattern. The adverse association
between depression and HF prognosis was not diminished after
adjustment for variables commonly considered to be confounding
factors in this population—age, New York Heart Association func-
tional class, baseline ejection fraction, and etiology of HF—suggesting
that major depression independently affects prognosis in HF.
We observed that the predictive ability of the BDI score (10
vs. 10) was more powerful at 3 months than at 12 months, when
it diminished somewhat. In contrast, the prognostic ability of
major depression appeared stronger over time. Given our under-
standing of HF, and the limited existing knowledge of its inter-
action with psychiatric disorders, we therefore consider a standard-
ized diagnostic interview to be necessary in addition to self-
administered instruments.
We are pleased our findings have been reproduced to a certain
degree at different tertiary-care settings. Despite the limitations of
both studies, there should be little doubt about the adverse effects
of depression on the short-term prognosis of recent inpatients with
HF. Whether such an adverse effect carries over to the long term
and whether treatment of depression can improve these poorer
outcomes demand study. The prognostic association between
depression and clinically stable HF also must be examined.
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We thank Dr. Jiang and colleagues for their thoughtful comments.
We were pleased to read their well-done study (1) published
almost concurrently with ours (2). Whereas their study shares a
number of similarities with ours, it also presents a number of
differences that might explain why the association of depression
with mortality was stronger in their study than in ours. First, as
these investigators point out, the assessment of depression was
different in the two studies.
Second, the populations of heart failure (HF) patients also
differed. In the attempt to restrict HF to cases of ischemic or
hypertensive etiology, we included predominantly elderly patients
(50 years and older), and the mean age of our sample was 73 years.
In contrast, Jiang and colleagues enrolled patients 18 years and
older. As a result, their population was much younger and most
likely it included a broader variety of HF etiology.
Third, while we assessed mortality at six months, Jiang et al.
assessed this outcome at three months and one year. The associ-
ation of depression with death may vary according to length of
follow-up. These investigators, for example, observed that major
depression was more strongly associated with mortality at one year
than at three months. At three months, this association was not
significant in their study, and the point estimate was not very
different from our estimate for “severe depression” at six months.
Therefore, it might be that if a longer follow-up were available in
our study, we would have observed a stronger association as well.
Fourth, while Jiang and colleagues adjusted for a number of
potential confounders, they did not include in their models a
number of covariables that were adjusted for in our study,
including race, education, previous hospitalizations for HF, dia-
betes, systolic blood pressure, serum creatinine and patient’s
self-reported disability level (number of limitations in activities of
daily living). Our study, therefore, might have obtained a tighter
control for potential confounders, especially those factors related to
disease severity and comorbidity. We do not believe that model
overfitting was a problem in our analysis, because the relative risk
estimate declined toward the null with progressive adjustment for
potential confounders, and because a reduced model provided
similar results.
However, in our study, depression was still associated with
substantial (although nonsignificant) mortality risk. Patients with
severe depression had 68% higher mortality risk compared with
nondepressed patients, and there was a dose-response relationship
with mortality according to severity of depressive symptoms. As we
pointed out in our study, our main focus was the examination of
the association of depression with functional decline. Our study
was not powered to examine mortality as a separate end point, and
a larger study might have found such a mortality difference to be
statistically significant. We concur with Dr. Jiang and colleagues
that, based on the results of both studies, depression poses serious
adverse effects on the outcomes of patients with HF.
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